Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ACS defined as a new pulmonary infiltrate involving at least one segment of the lung on a chest x-ray or chest CT scan with 2 or more of the following: chest pain, tachypnea, dyspnea, cough, hypoxemia, or body temperature greater than or equal to 38.0 degrees Celsius~* Hemoglobin electrophoresis confirming HbSS, SC, or B0 (historical records sufficient)~* Age greater than or equal to 18~Exclusion Criteria:~* Any absolute contraindication to heparin~* Platelet count less than 50 per microliter (current admission)~* Historical diagnosis of moyamoya disease as documented in medical records~* Historical diagnosis of proliferative retinopathy as documented in medical records~* Current participation in a chronic exchange transfusion program~* Underlying hypercoagulable disorder other than sickle cell disease~* Currently receiving therappeutic anticoagulation~* Currently receiving antiplatelet agents~* Currently receiving estrogen containing oral contraceptives~* Chest CT scan documented PE performed as standard of care prior to study enrollment (current admission)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Unfractionated heparin (Type: EXPERIMENTAL): Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
- Standard of care (Type: NO_INTERVENTION): Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.

Based on this trial design, predict the completion outcome and termination type (if applicable).